Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) SVP Laurie Keating sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the completion of the transaction, the senior vice president now owns 41,500 shares in the company, valued at $5,639,435. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) traded down $1.01 on Tuesday, hitting $127.00. 869,532 shares of the stock were exchanged, compared to its average volume of 1,149,262. Alnylam Pharmaceuticals, Inc. has a 12 month low of $35.98 and a 12 month high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). The firm had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.21) EPS. equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -5.21 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the stock. FMR LLC increased its stake in Alnylam Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after purchasing an additional 815,270 shares during the last quarter. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 13.4% during the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after purchasing an additional 759,295 shares during the last quarter. BlackRock Inc. increased its stake in Alnylam Pharmaceuticals by 9.3% during the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after purchasing an additional 441,957 shares during the last quarter. Baillie Gifford & Co. boosted its holdings in shares of Alnylam Pharmaceuticals by 2.9% during the second quarter. Baillie Gifford & Co. now owns 3,431,316 shares of the biopharmaceutical company’s stock valued at $273,681,000 after acquiring an additional 96,805 shares during the period. Finally, Orbimed Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 69.7% during the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock valued at $127,453,000 after acquiring an additional 445,600 shares during the period. Institutional investors and hedge funds own 88.43% of the company’s stock.

Several brokerages recently weighed in on ALNY. Stifel Nicolaus reaffirmed a “buy” rating and set a $56.00 target price (up from $47.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 10th. Chardan Capital reissued a “buy” rating and issued a $124.00 price objective (down from $131.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 10th. Jefferies Group increased their price objective on shares of Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday, September 26th. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the company an “equal weight” rating in a report on Thursday, August 10th. Finally, Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the company from $62.00 to $163.00 in a report on Monday, October 2nd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and seventeen have given a buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and an average price target of $121.85.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/05/alnylam-pharmaceuticals-inc-alny-svp-sells-4076700-00-in-stock.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.